SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "Lon

Actuate Therapeutics reported positive top-line findings from a Phase II trial of the glycogen synthase kinase 3 beta (GSK-3β) inhibitor elraglusib in combination with chemotherapy, demonstrating a clinically meaningful survival benefit in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The data were presented at the American Society of Clinical Oncology (ASCO) annual meeting on Saturday.The Actuate-1801 Part 3B study evaluated elraglusib plus gemcitabine/n

Vera Therapeutics said its experimental kidney disease treatment atacicept met the primary endpoint of a Phase III trial, reducing levels of protein in the urine by 46% from baseline and 42% compared to placebo at 36 weeks. The results exceeded the 30% placebo-adjusted threshold that Jefferies analysts had recently identified as the bar for clinical meaningfulness, sending Vera shares up more than 67% on Monday.The pivotal ORIGIN trial enrolled 431 adults with IgA nephropathy (IgAN) who received

After teasing in April that Enhertu (trastuzumab deruxtecan) met the primary progression-free survival (PFS) endpoint in a late-stage study of patients with HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo have now shared detailed data supporting front-line use of the HER2-directed antibody-drug conjugate (ADC).Enhertu is currently approved as a second-line treatment for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer.The Phase III DESTINY-Breast09 stud

Novartis on Monday announced upbeat interim analysis results from a Phase III study of its PSMA-targeted radioligand therapy Pluvicto (lutetium 177 vipivotide tetraxetan), which in combination with hormone therapy boosted radiographic progression-free survival (rPFS) over hormone therapy alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC).This marks the third consecutive positive late-stage readout for Pluvicto, following the VISION trial which led to its FDA approval for

Sanofi entered into an agreement to buy Blueprint Medicines for up to $9.5 billion, expanding the French drugmaker's rare immunological disease portfolio and early-stage pipeline in immunology. The deal — announced Monday — includes $129 per share in cash, representing an equity value of around $9.1 billion, as well as a contingent value right (CVR) worth about $400 million.The purchase "enhances our pipeline and accelerates our transformation into the world's leading immunology company," remark

Bristol Myers Squibb is joining a number of peers in the race to bring bispecific antibodies targeting PD-(L)1xVEGF to market after paying $1.5 billion upfront for rights to co-develop BioNTech's BNT327 across numerous solid tumour types. The deal — announced Monday and potentially worth over $10 billion in biobucks — also represents another asset in the space that originates from a Chinese biotech, mirroring recent moves made by Pfizer and Merck & Co.BNT327, which targets PD-L1 and VEGF-A, foun

Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. Continue R

SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at l

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord injury (SCI). Study also showed a positive trend in the secondary endpoint evaluating change in “GRASSP” score, a measure designed specifically to assess hand function in people with cervical injuries. As the first pharmaceutical candidate to sho